Saratov JOURNAL of Medical and Scientific Research

Pedicled retinal pigment epithelium — choroid graft autotranslocation in scarred age-related macular degeneration


The purpose of the study is to analyse the effectiveness of pedicled RPE (retinal pigment epithelium) — choroid graft autotranslocation in scarred neovascular age-related macular degeneration (AMD) treatment. Material and Methods. Pedicled RPE — choroid graft autotranslocation was performed on 8 patients with scarred wet AMD. Follow-up was from 6 to 30 months. Visual acuity, ophthalmoscopy, optical coherent tomography and indocian-green angiography were analysed. Results. The average visual acuity increased from 0.009±0.006 to 0.018±0.022 (p=0.15). Visual acuity increased in 50% of the patients. In 50% of patients visual acuity decreased, which was associated with proliferative vitreoretinopathy in post-op period with retinal detachment formation. No cases of choroidal neovascularization recurrence were detected. According to angiography data normal choroidal perfusion in the rotated RPE — choroid patch was revealed after 1 month during the follow-up examination. Conclusion. Pedicled RPE — choroid graft translocation can be successively performed in case of scarred neovascular age-related macular degeneration.

1. Boiko EV, Sosnovskii SV, Berezin RD, et al. Antiangiogenic therapy in ophthalmology. Saint Petersburg: Military Medical Academy n. a. S.M. Kirov, 2013; 292 p.
2. Klein R, Klein В, KnudtsonM,etal. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007 Feb; 114(2): 253-62.
3. Bikbov MM, Zainullin RM, Gilmanshin TR, et al. Prevalence and Associated Factors of Age-Related Macular Degeneration in a Russian Population: The Ural Eye and Medical Study. Am J Ophthalmol 2020 Feb; 210:146-57. DOI: 10.1016/j. ajo. 2019.10.004.
4. Roomasa C, Raafay S, Saghar B, et al. Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes. Am J Ophthalmol 2015; 159:9-19.
5. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 2012; 87:77-88. DOI: 10.1016/j. mayocp. 2011.10.001.
6. Boulanger-Scemama E, Sayag D, Ha Chau Tran T, et al. Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice. J Fr Ophtalmol 2016; Oct; 39 (8): 668-74. DOI: 10.1016/j. jfo. 2016.06.001.
7. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond) 2016 Nov; 30 (11): 1526. DOI: 10.1038/eye. 2016.202.
8. De Silva SR, Bindra MS. Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent. Eye (Lond) 2016 Jul; 30 (7): 952-7. DOI: 10.1038/eye. 2016.67.
9. Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. BrJ Ophthalmol 2012; 96: 21-3. DOI: 10.1136/bjo. 2011.203893.
10. Parolini B, Di Salvatore A, Pinackatt SJ, et al. Long-term results of autologous retinal pigment epithelium and choroid transplantation for the treatment of exudative and atrophic maculopathies. Retina 2020 Mar; 40 (3): 507-20. DOI: 10.1097/IAE. 0000000000002429.

2020_02-1_658-662.pdf877.26 KB

No votes yet